

**Procter & Gamble - I.P. Division****IMPORTANT CONFIDENTIALITY NOTICE**

The documents accompanying this telexcopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telexcopied information is strictly prohibited. If you have received this telexcopy in error, please immediately notify us by telephone (collect) to arrange for return of the telexcopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND  
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

**RECEIVED  
CENTRAL FAX CENTER**

**FEB 23 2004**

**TO: United States Patent and Trademark Office**  
**Attn: Group Art Unit 1751**  
**Fax No. 703-872-9306**

*I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on February 23, 2004, to the above-identified facsimile number.*

Cynthia L. Clay (Signature)

**FROM: Cynthia L. Clay (Typed or printed name of person signing Certificate)**

Fax No. (513) 626-1355

Phone No. (513) 626-0575

Listed below are the item(s) being submitted with this Certificate of Transmission:\*\*

- 1) Information Disclosure Statement, and one copy for authorization to charge fee to Deposit Account;
- 2) PTO Form PTO/SB08

Number of Pages Including this Page: **8**

Inventor(s): Lorenzi et al.  
 S.N.: 10/705,492  
 Filed: 11/10/2003  
 Conf. No.: 5146  
 Case: 8911MC

Comments:

\*\*Note: Each paper must have its own certificate of transmission, OR this certificate must identify each submitted paper.

P&amp;G Case 8911MC

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of :  
**M. P. LORENZI ET AL.** : Confirmation No. 5146  
 Serial No. 10/705,492 : Group Art Unit 1616  
 Filed November 10, 2003 : Examiner Not Assigned

RECEIVED  
CENTRAL FAX CENTER  
FEB 23 2004

For Hotmelt Compositions and Related Articles

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
 P. O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1.  37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2.  37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct, but before 1<sup>st</sup> O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

3.  37 C.F.R. §1.97(b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

4.  Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

5.  37 C.F.R. §1.97(c) with fee payment - (use after 1<sup>st</sup> Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

(1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8911M, U.S. Patent Application Serial No. 10/421.258, filed April 23, 2003. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

(2) Copies of the cited documents are enclosed.

OR

(3) Copies of all said documents, except document No.'s \_\_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s \_\_\_\_\_ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s \_\_\_\_\_ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

(4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

(5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

By Cynthia L. Clay  
Cynthia L. Clay  
Attorney for Applicants  
Registration No. 54,930  
(513) 626-0575

February 23, 2004

Customer No. 27952

(IDS.doc)  
(Last Revised 4/4/2003)

P&amp;G Case 8911MC

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

M. P. LORENZI ET AL. : Confirmation No. 5146  
Serial No. 10/705,492 : Group Art Unit 1616  
Filed November 10, 2003 : Examiner Not Assigned

For Hotmelt Compositions and Related Articles

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1.  37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2.  37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct, but before 1<sup>st</sup> O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

3.  **37 C.F.R. §1.97 (b)(4) - (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)**

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

4.  **Information to be Considered with CPA Filing.** This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

5.  **37 C.F.R. §1.97(c) with fee payment - (use after 1<sup>st</sup> Office Action & before Final Office Action or Notice of Allowance)**

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., *Ex parte Quayle*) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

**ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:**

(1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. 8911M, U.S. Patent Application Serial No. 10/421,258, filed April 23, 2003. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

(2) Copies of the cited documents are enclosed.

OR

(3) Copies of all said documents, except document No.'s \_\_\_\_\_, were submitted and considered in parent application U.S. Patent Application Serial No. \_\_\_\_\_, filed \_\_\_\_\_. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s \_\_\_\_\_ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s \_\_\_\_\_ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.

(4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is provided.

(5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

Additional information is attached.

Respectfully submitted,

By Cynthia L. Clay  
Cynthia L. Clay  
Attorney for Applicants  
Registration No. 54,930  
(513) 626-0575

February 23, 2004

Customer No. 27732

(IDS.doc)  
(Last Revised 4/4/2003)

Please type a plus sign (+) inside this box → [+]

PTO/SB08A/B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

COMPLETE IF KNOWN

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 1

Application Number	10/705,492
Confirmation Number	5146
Filing Date	11/10/2003
First Named Inventor	Marc Paul Lorenzi
Group Art Unit	1616
Examiner Name	
Attorney Docket Number	8911MC

### U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.	DOCUMENT NUMBER Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
01	US-4,342,314	08/03/1982	Radel et al.		
02	US-4,447,294	05/08/1984	Osbom		
03	US-4,529,480	07/16/1985	Trohan		
04	US-4,603,176	07/29/1986	Bjorkquist		
05	US-4,629,643	12/16/1986	Curro et al.		
06	US-4,637,859	01/20/1987	Trohan		
07	US-4,673,525	06/16/1987	Small et al.		
08	US-4,687,153	08/18/1987	McNeil		
09	US-4,981,557	01/01/1991	Bjorkquist		
10	US-5,085,736 A	02/04/1992	Bjorkquist		
11	US-5,138,002 A	08/08/1992	Bjorkquist		
12	US-5,223,096 A	06/29/1993	Phan et al.		
13	US-5,262,007 A	11/16/1993	Phan et al.		
14	US-5,264,082 A	11/23/1993	Phan et al.		
15	US-5,679,222 A	10/21/1997	Rasch et al.		
16	US-6,025,049 A	02/15/2000	Gordon et al.		
17	US-6,180,052 B1	01/30/2001	Gordon et al.		

### FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
18	WO 99/21532 A1	05/06/1999	Procter & Gamble			
19	WO 99/37200 A1	07/29/1999	Procter & Gamble			
20	WO 02/00819 A1	06/22/2001	S. C. Johnson & Son, Inc.			

### NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
	21	Franz, T. J., "Percutaneous Absorption. On The Relevance of In Vitro Data", J. Invest. Dermatol., Vol. 64, No. 1, pp. 190-195. (1975)	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.